Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29610885 | 1.00 | NPC1 (1.00) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL29163637 | 0.85 | NPC1 (0.74) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL29420231 | 0.85 | NPC1 (0.74) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL29128053 | 0.85 | NPC1 (0.74) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL30666441 | 0.85 | NPC1 (0.74) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL28632326 | 0.84 | NPC1 (0.73) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL4946651 | 0.82 | NPC1 (0.70) | NPC1RAB9APKMPOLBKDM4E | |
| SCHEMBL29611011 | 0.82 | NPC1 (1.00) | NPC1RAB9APKMKDM4EMEN1 | |
| SCHEMBL5579208 | 0.82 | NPC1 (1.00) | NPC1RAB9APKMKDM4EMEN1 | |
| SCHEMBL29874794 | 0.81 | NPC1 (1.00) | NPC1RAB9APKMKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| CN-113403635-B | Method for preparing N-substituted pyrrolidone derivative | 五邑大学 | 2022-05-03 | — | — | CN | disclosed |
| CN-113403635-A | Method for preparing N-substituted pyrrolidone derivative | 五邑大学 | 2021-09-17 | — | — | CN | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| CN-104803905-A | Method for synthesizing isoindoline-1-ketone derivative | UNIV FUDAN | 2015-07-29 | — | — | CN | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | NPC1 1796/4885RAB9A 3954/4885PKM 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.